Clinical trials: Antiplatelet Drug
Acute Coronary Syndrome
Prevention of Cardiovascular Events by Antiplatelet Agents After Acute Coronary Syndrome
Prevention of cardiovascular events by antiplatelet agents after acute coronary syndrome
- Trial name
- AReMIS (NCT01952392)
- Where
- France
- Volunteers
- 4,992 people
- Sponsor
- AstraZeneca
Coronary Artery Lesions
XIENCE 90: A Safety Evaluation of 3-month DAPT After XIENCE Implantation for HBR Patients.
XIENCE 90 study is a prospective, single arm, multi-center, open label trial to evaluate the safety of 3-month dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary…
- Trial name
- NCT03218787
- Testing
- XIENCE, DAPT
- Where
- 101 sites in United States
- Volunteers
- 2,047 people
- Sponsor
- Abbott Medical Devices
Coronary Disease, Drug Eluting Stent
Comparison One vs Six Months of Dual Antiplatelet Therapy After Implanted Firehawk TM Stent in High Bleeding Risk Patients With Coronary Artery Disease
This study is to assess the clinical non-inferiority of 1 month (short-term) vs 6 months (long-term) of dual anti-platelet therapy in patients undergoing percutaneous intervention implanted sirolimus -eluting stent with abluminal…
- Conditions
- Coronary Disease, Drug Eluting Stent, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy
- Trial name
- NCT03287167
- Testing
- 1 month DAPT, 6 months DAPT
- Where
- China
- Volunteers
- 1,720 people
- Sponsor
- Shanghai MicroPort Medical (Group) Co., Ltd.
Platelet Aggregation Inhibitors, NSTEACS
Efficacy and Safety in Patients With Acute Coronary Syndrome Without ST-Segment Elevation
To evaluate the efficasy and safety of SR25990C(loading dose:300mg, maintenance dose:75mg/day) in comparison with the standard Japanese treatment(ticlopidine) in patients with acute coronary syndrome without ST-segment elevation…
- Trial name
- NCT00325390
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 800 people
- Sponsor
- Sanofi
Acute Coronary Syndrome, Stroke
Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SP-8008
This is a single-centre, double-blind, randomised, placebo-controlled single oral-dose escalation study in healthy male subjects. It is planned to enrol approximately 48 subjects into up to 6 planned dose level cohorts.
- Trial name
- NCT04770194
- Testing
- SP-8008 Prototype Capsule A, SP-8008 Prototype Capsule B
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
Intracranial Arteriosclerosis, Intracranial Artery Stenosis
Comparison Three vs Six Months of Dual Anti-platelet Therapy After Sirolimus-eluting Stent Implantation
This study is a prospective, multicenter, open-label, randomized controlled clinical trial, aims to assess the clinical non-inferiority of 3 months (short-term) vs 6 months (long-term) of Dual Anti-Platelet Therapy (DAPT) in…
- Conditions
- Intracranial Arteriosclerosis, Intracranial Artery Stenosis, Drug-Eluting Stents
- Trial name
- NCT06857045
- Testing
- NOVA intracranial sirolimus-eluting stent system
- Where
- China
- Sponsor
- Sino Medical Sciences Technology Inc.
Myocardial Infarction (MI)
Patient Characteristics, Persistence to Treatment and Outcome Events in Patients Treated With Ticagrelor 60 mg After Myocardial Infarction in Real-world Clinical Practice
This is an observational study based on secondary data extracted from multiple register-based data sources in the US and Europe (Sweden, United Kingdom, Italy, Germany).
- Trial name
- ALETHEIA (NCT04568083)
- Where
- 6 sites in United States, Germany and 3 more
- Volunteers
- 7,035 people
- Sponsor
- AstraZeneca
Cardiovascular Disease, Overweight
Effect of Platelet Inhibition According to Clopidogrel Dose in Patients With Body Mass Index ≥ 27
The purpose of the study is to determine whether administration of 150 mg clopidogrel is effective in reducing the one-year incidence of thromboischemic events in patients with high on-clopidogrel platelet reactivity compared to…
- Trial name
- PLATO-dose (NCT01509365)
- Testing
- clopidogrel
- Where
- Tunisia
- Volunteers
- 116 people
- Sponsor
- Les Laboratoires des Médicaments Stériles
Stable Angina, Myocardial Infarction
Safety Evaluation of Clopidogrel Sulfate in Patients With Stable Angina/Old Myocardial Infarction to Whom Percutaneous Coronary Intervention is Being Planned
Primary objective: To evaluate whether 12 weeks of clopidogrel is superior to ticlopidine in terms of lower risk of the safety events of interest in patients with stable angina (SA) or old myocardial infarction (OMI) to which…
- Trial name
- CLEAN (NCT00821834)
- Testing
- clopidogrel (SR25990), ticlopidine
- Where
- Japan
- Volunteers
- 1,003 people
- Sponsor
- Sanofi
Acute Coronary Syndrome
A Double-Blind Study of E5555 in Japanese Patients With Acute Coronary Syndrome
The purpose of this study is to assess the safety and tolerability of E5555 in Japanese patients with acute coronary syndrome.
- Trial name
- NCT00619164
- Testing
- E5555
- Where
- 33 sites in Japan
- Volunteers
- 240 people
- Sponsor
- Eisai Co., Ltd.
Bleeding Disorder, Ischemic Stroke
XIENCE 28 USA Study
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR)…
- Conditions
- Bleeding Disorder, Ischemic Stroke, Hemorrhagic Stroke, Hematological Diseases
- Trial name
- NCT03815175
- Testing
- XIENCE, DAPT (aspirin and/or P2Y12 receptor inhibitor)
- Where
- 111 sites in United States, Austria and 13 more
- Volunteers
- 1,605 people
- Sponsor
- Abbott Medical Devices
Chronic Total Occlusion of Coronary Artery, Vascular Disease
XIENCE V® USA Dual Antiplatelet Therapy (DAPT) Cohort
XIENCE V USA is a prospective, multi-center, multi-cohort postapproval study. The objectives of this study are To evaluate XIENCE V EECSS continued safety and effectiveness during commercial use in real world settings, and To…
- Conditions
- Chronic Total Occlusion of Coronary Artery, Vascular Disease, Myocardial Ischemia, Coronary Artery Stenosis
- Trial name
- XVU-AV DAPT (NCT01106534)
- Testing
- clopidogrel + aspirin OR prasugrel + aspirin, XIENCE V Everolimus Eluting Coronary Stent System (XIENCE V EECSS)
- Where
- 144 sites in United States
- Volunteers
- 870 people
- Sponsor
- Abbott Medical Devices
Acute Coronary Syndrome
Study of LC23-1306 in Healthy Male Subjects
This will be a dose block-randomized, double-blind, active and placebo controlled, single and multiple dosing, dose-escalation study to evaluate tolerability, safety and pharmacokinetic/pharmacodynamic characteristics.
- Trial name
- NCT01526577
- Testing
- LC23-1306, Ticagrelor
- Where
- South Korea
- Volunteers
- 113 people, healthy volunteers welcome
- Sponsor
- LG Life Sciences
Arterial Obstructive Diseases, Coronary Disease
Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)
The object of the study is to determine whether different doses of SCH 530348, when added to standard medical care in persons undergoing percutaneous coronary intervention, will increase the risk of bleeding.
- Trial name
- NCT00132912
- Testing
- SCH 530348
- Volunteers
- 1,030 people
- Sponsor
- Merck Sharp & Dohme LLC
Sickle Cell Disease
A Study to Compare if the Uptake of Ticagrelor in the Body Differs When Different Tablets Are Administered
To evaluate the relative bioavailability of ticagrelor for the different formulations. A randomized cross-over design has been chosen to minimize the effects of between-subject variability and any period effects on the overall…
- Trial name
- NCT03126695
- Testing
- Ticagrelor granule, Ticagrelor pediatric tablets, Ticagrelor pediatric tablets suspended in water
- Where
- Germany
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Healthy
Influence of Rabeprazole on the Magnitude of the Antiplatelet Action of Clopidogrel
The purpose of this study is to assess, whether the administration of a proton pump inhibitor, Rabeprazole, has a negative effect on the activity of a concomitantly administered blood thinner drug.
- Trial name
- CLARA (NCT00989300)
- Testing
- Treatment A - rabeprazole, Treatment B - omeprazole
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Janssen Cilag S.A.S.
Stable Angina, Silent Myocardial Ischemia
Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.
The main objective of the SENIOR study is to establish the efficacy and safety of the everolimus eluting stent with a biodegradable abluminal polymer (SYNERGY II) associated with a short dual antiplatelet therapy (DAPT) in…
- Conditions
- Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome
- Trial name
- SENIOR (NCT02099617)
- Testing
- Percutaneous Coronary Intervention (PCI) with short DAPT duration with Synergy II stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Omega stent, Percutaneous Coronary Intervention (PCI) with short DAPT duration with Rebel stent
- Where
- 44 sites in Belgium, Finland and 7 more
- Volunteers
- 1,200 people
- Sponsor
- Ceric Sàrl
Antiplatelet Drug
Antiplatelet Thrombolysin (Anfibatide) Phase 1 Clinical Trial in Healthy Volunteers
This is a phase 1, dose-escalation, and multidose study, aiming to investigate the tolerability, safety and pharmacokinetics of Anfibatate in healthy subjects.
- Trial name
- NCT04404790
- Testing
- Anfibatide 5 IU/60kg, Anfibatide 5 IU/60kg +0.002 IU/kg/h, Anfibatide 5 IU/60kg +0.004 IU/kg/h
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Lee's Pharmaceutical Limited
Cerebral Infarction
Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment
The primary objective is to compare the safety of clopidogrel 50mg and 75mg in cerebral infarction with respect to incidence of bleeding adverse events.
- Trial name
- NCT00386191
- Testing
- clopidogrel (SR25990C)
- Where
- Japan
- Volunteers
- 1,110 people
- Sponsor
- Sanofi
Stable Coronary Disease, Unstable Coronary Disease
Brazilian and Italian Evaluation of Safety Using Tacrolimus-eluting Stent With Short-term Dual Antiplatelet Regimen
To evaluate the safety and efficacy of the Janus OPTIMA Tacrolimus-Eluting Stent (Optima TES, CID) for the treatment of de novo coronary lesions when associated with short-term (two months) dual antiplatelet (aspirin +…
- Conditions
- Stable Coronary Disease, Unstable Coronary Disease, Documented Silent Ischemia
- Trial name
- BEST (NCT01122719)
- Testing
- Drug Eluting Stent
- Where
- 2 sites in Brazil, Italy
- Volunteers
- 16 people
- Sponsor
- CID - Carbostent & Implantable Devices